This article summarized the latest R&D progress of Trofinetide, the Mechanism of Action for Trofinetide, and the drug target R&D trends for Trofinetide.
This article summarized the latest R&D progress of Dexmethylphenidate Hydrochloride, the Mechanism of Action for Dexmethylphenidate Hydrochloride, and the drug target R&D trends for Dexmethylphenidate Hydrochloride.
Nova Therapeutics, a biotech firm specializing in Influenza A treatments, received US FDA approval for its IND application for influenza A suppressant, VNT-101.
This article summarized the latest R&D progress of Colesevelam Hydrochloride, the Mechanism of Action for Colesevelam Hydrochloride, and the drug target R&D trends for Colesevelam Hydrochloride.
This article summarized the latest R&D progress of Clindamycin Palmitate Hydrochloride, the Mechanism of Action for Clindamycin Palmitate Hydrochloride, and the drug target R&D trends for Clindamycin Palmitate Hydrochloride.
Merck reported that the phase III KEYNOTE-A39/EV-302 test halted disease progression in certain patients with local or metastatic urothelial cancer who hadn't received prior treatment.
This article summarized the latest R&D progress of Clemastine Fumarate, the Mechanism of Action for Clemastine Fumarate, and the drug target R&D trends for Clemastine Fumarate.
This article summarized the latest R&D progress of Ciprofloxacin Hydrochloride, the Mechanism of Action for Ciprofloxacin Hydrochloride, and the drug target R&D trends for Ciprofloxacin Hydrochloride.
Genmab Unveils EU Commission's Authorization for TEPKINLY® (epcoritamab) to Treat Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL) in Adults.